Arrowhead to Present at RBC Capital Markets’ Global Healthcare Conference

PASADENA, Calif. — February 20, 2014 — Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that President and CEO, Christopher Anzalone, Ph.D., will present at the 2014 RBC Capital Markets’ Global Healthcare Conference on Wednesday, February 26, 2014 at 3:30 p.m. EST at the New York Palace Hotel.

A live webcast of the presentation can be accessed by visiting the News & Events section of the company’s website, http://www.arrowheadresearch.com/presentations. A replay will also be archived on the website and available for 90 days.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology.

For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company’s email list to receive news directly, please send an email to ir@arrowres.com.